A clinical study of chimeric-antigen-receptor-tranduced T cells in the treatment of B-cell hematologic malignancies

Trial Profile

A clinical study of chimeric-antigen-receptor-tranduced T cells in the treatment of B-cell hematologic malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 May 2017

At a glance

  • Drugs CAR-T cell therapies (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; B-cell leukaemia; Lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Hebei Senlang Biotechnology
  • Most Recent Events

    • 26 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top